Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Autor: Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga

Publikováno v: The Lancet Oncology. 19:1449-1458

Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43dd418b74f44f31f1f62f0d52fde6f
https://doi.org/10.1016/s1470-2045(18)30685-5

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study

Autor: Jie Jin, Jun Zhu, Huiqiang Huang, Brendan Rooney, Osmanov Ea, Jiri Mayer, Tadeusz Robak, Halyna Pylypenko, Olga Samoilova, Gregor Verhoef, Helgi van de Velde, Juliana Pereira, Ting Liu, Noppadol Siritanaratkul, Franco Cavalli, Xiaonan Hong, Rumiko Okamoto, Lixia Pei

Publikováno v: Leukemia & Lymphoma. 60:172-179

The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f08a24dc974f337016a74acebf3784f
https://doi.org/10.1080/10428194.2017.1321750

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Autor: Michael Crump, Ofer Shpilberg, Sven de Vos, Dixie Lee Esseltine, Adriana Teixeira, Weimin Li, Joanna Romejko-Jarosinska, Adriana Scheliga, George Mulligan, Yusri Elsayed, Andrew Cakana, Osmanov Ea, Helgi van de Velde, Panteli Theocharous, Fritz Offner, Henitz Erin Devay, Michael E. Schaffer, Bertrand Coiffier, Simon Rule, Jayaprakash Karkera, Alice Shapiro, Jiri Mayer, Deborah Ricci, Dana Gaffney, Xiaonan Hong, Reyna Favis, Pier Luigi Zinzani

Publikováno v: Clinical Cancer Research. 19:2551-2561

Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib–rituximab versus rituximab in the phase III LYM-3001 study. Experimental Design: A tot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe20d8672aa661248cb925a0d9b9ef7
https://doi.org/10.1158/1078-0432.ccr-12-3069

[The experience of reforming primary health care in conditions of increasing of population average age].

Autor: Nikolaeva IV; The Department of Health Care and Social Care of Population of the Belgorod Oblast, 308005, Belgorod, Russia., Zhernakova NI; The Federal State Autonomous Educational Institution of Higher Education 'The Belgorod State National Research University', 308015, Belgorod, Russia, zhernakova@bsu.edu.ru., Osmanov EA; The Federal State Budget Educational Institution of Higher Education 'The G. R. Derjavin Tambov State University' 392000, Tambov, Russia., Lebedev TJ; The Federal State Autonomous Educational Institution of Higher Education 'The Belgorod State National Research University', 308015, Belgorod, Russia., Manjakov RR; The Federal State Budget Educational Institution of Higher Education 'The G. R. Derjavin Tambov State University' 392000, Tambov, Russia.

Publikováno v: Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny [Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med] 2020 Nov; Vol. 28 (6), pp. 1374-1379.

[Specifics of spa-based rehabilitation of severe forms of spastic mobility loss of patients with cerebral palsy].

Autor: Osmanov EA; Evpatoria Military Children's Clinical Sanatorium named after E.P. Glinki, Ministry of Defense of Russia, Evpatoria, Russia., Larina NV; The Department of Nerve Diseases and Neurosurgery, Faculty of First Medical School, Medical Academy named after S.I. Georgievsky FGAOU VO 'Crimean Federal University named after V.I. Vernadsky', Simferopol, Russia., Vlasenko SV; The Scientific Research Institute of Children's Balneology, Physiotherapy and Medical Rehabilitation, Evpatoria, Russia., Golubova TF; The Scientific Research Institute of Children's Balneology, Physiotherapy and Medical Rehabilitation, Evpatoria, Russia., Marusich II; Evpatoria Military Children's Clinical Sanatorium named after E.P. Glinki, Ministry of Defense of Russia, Evpatoria, Russia., Kushnir GM; The Department of Nerve Diseases and Neurosurgery, Faculty of First Medical School, Medical Academy named after S.I. Georgievsky FGAOU VO 'Crimean Federal University named after V.I. Vernadsky', Simferopol, Russia.

Publikováno v: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (6), pp. 47-52.